Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry

Darmstadt, Germany and St. Louis, MO, September 22, 2014 – Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich today announced that they have entered into a definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion), establishing one of the leading players in the $130 billion global life science industry.

Merck Serono Investor & Analyst Day 2014

Merck underscored today that its biopharmaceutical business is well on track. This is reflected by the successful execution of growth initiatives as well as progress in the pipeline, particularly in Immuno-Oncology, among others, and in the field of Biosimilars, where Merck plans to step up investments next year.

More room for innovation

Merck will expand the Darmstadt site into a contemporary, attractive global headquarters. The Innovation Center is at the heart of the ONE Global Headquarters initiative. Merck is focusing on innovations to secure the company's future success. The future Innovation Center is where employees will find a creative atmosphere and space for interdisciplinary cooperation on projects.

Merck grows organically in all four businesses in the second quarter

“We had a solid second quarter,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck. “This was primarily due to our healthy operating business.“
Merck also confirmed its full-year forecast.

 

Media Services

Sachdev and Kley
CEO Karl-Ludwig Kley and Sigma-Aldrich CEO Rakesh Sachdev
zoom in
Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry
Darmstadt, Germany and St. Louis, MO, September 22, 2014 – Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich today announced that they have entered into a definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion), establishing one of the leading players in the $130 billion global life science industry.
 
Belén Garijo appointed new member of the Executive Board
Belén Garijo appointed new member of the Executive Board
zoom in
Merck Strengthens Executive Board
Darmstadt, Germany, September 18, 2014 – Merck today announced that the Board of Partners has promoted Stefan Oschmann (57) to the position of Deputy CEO and Vice Chairman of the Executive Board. Concurrently, Belén Garijo (54) was appointed to the Executive Board to take over leadership for the Pharma business. The management changes will become effective as of January 1, 2015.
 
Merck Serono Investor & Analyst Day 2014
Merck Serono Investor & Analyst Day 2014
Merck Serono Investor & Analyst Day 2014
Darmstadt, Germany, September 18, 2014 – Merck’s biopharmaceutical businesses are well on track. This is reflected for example by the successful execution of growth initiatives and by progress in the pipeline. This progress can be seen particularly in Immuno-Oncology, among others. Additionally Merck plans to step up investments in its Biosimilars unit next year.
 
 
top

MERCK IN THE MEDIA

Merck in the Media
Read how Merck and its affiliates are covered by media outlets around the world

DOWNLOAD LIBRARY

Download Library
Download images, Media Kits and other material from our media download library

CALENDAR OF EVENTS

Calendar of Events
Find and register for upcoming Merck events

CONTACTS FOR JOURNALIST INQUIRIES

Media Team
Tel.: +49 6151 72-5000
Fax: +49 6151 72-3138
 

GENERAL INQUIRIES

Communications Center
Tel.: +49 6151 72-0
Fax: +49 6151 72-2000
 

MERCK FINANCIAL REPORT

2nd quarter 2014Merck Interim Report
Merck on Facebook
Merck on Twitter
 
  
Read more on M - The Explorer Magazine

Pioneering work for allergy patients

Whether allergies are due to heredity, environmental pollution or excessive hygiene, they are troublesome illnesses of the immune system whose effects should not be underestimated.

Read more on M - The Explorer Magazine
Read more on M - The Explorer Magazine

Partnerships for better early diagnosis

Few people know the symptoms of a head and neck tumor. Merck is therefore supporting head and neck tumor awareness week again this year.

Read more on M - The Explorer Magazine
Read more on M - The Explorer Magazine

Honeybees sweeten “Go Green” initiative

In the town of Aubonne on the north side of Lake Geneva in Switzerland, Merck Serono employees produce not only cutting-edge biotechnological medicines, but their own honey too.

Read more on M - The Explorer Magazine